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http://www.biomedcentral.com/1756-0500/5/240RESEARCH ARTICLE Open AccessMYOD-1 in normal colonic mucosa – role as a
putative biomarker?
Ramesh P Arasaradnam1,2*, M Nabil Quraishi1, Daniel Commane3, John C Mathers3 and Mike Bradburn4Abstract
Background: DNA methylation of promoter-associated CpG islands of certain genes may play a role in the
development of colorectal cancer. The MYOD-1 gene which is a muscle differentiation gene has been showed to be
significantly methylated in colorectal cancer which, is an age related event. However the role of this gene in the
colonic mucosa is not understood and whether methylation occurs in subjects without colon cancer. In this study,
we have determined the frequency of methylation of the MYOD-1 gene in normal colonic mucosa and investigated
to see if this is associated with established colorectal cancer risk factors primarily ageing.
Results: We analysed colonic mucosal biopsies in 218 normal individuals and demonstrated that in most individuals
promoter hypermethylation was not quantified for MYOD-1. However, promoter hypermethylation increased
significantly with age (p< 0.001 using regression analysis) and this was gender independent. We also showed that
gene promoter methylation increased positively with an increase in waist to hip (WHR) ratio – the latter is also a
known risk factor for colon cancer development.
Conclusions: Our study suggests that promoter gene hypermethylation of the MYOD-1 gene increases significantly
with age in normal individuals and thus may offer potential as a putative biomarker for colorectal cancer.
Keywords: MYOD-1, Colorectal cancer, Age, Promoter methylationBackground
Genetic alterations leading to mutations in tumour sup-
pressor genes and oncogenes only characterise 10% of
colorectal cancers. Various genetic and epigenetic modi-
fications that lead to heritable changes in gene function
but unrelated to changes in DNA sequence are under-
stood to be mechanisms that cause development of can-
cer [1-4]. One of the most studied changes that are
linked to neoplasia is aberrant DNA methylation. Gene
specific hypermethylation can result in reduced gene ex-
pression/silencing with consequent detriment to the
colonocyte, particularly if key genes such as tumour sup-
pressor genes are involved [5,6]. It has also been sug-
gested that detecting hypermethylation of these genes in
blood or stool samples may prove to be a non invasive
method of detecting those at risk of colon cancer [7].* Correspondence: r.arasaradnam@warwick.ac.uk
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distribution, and reproduction in any mediumDNA hypermethylation has been investigated exten-
sively in colorectal cancer and other pre-malignant dis-
eases and many genes specifically affected by CpG
methylation have been identified. The MYOD-1 gene is
one such gene which is located on chromosome 11, is
mainly expressed in skeletal muscle. Several studies have
demonstrated hypermethylation of this gene in tumour
tissue and to a lesser extent in the normal adjacent colon
[8,9]. The function of this gene is of particular interest as
although it is a specific muscle regulator, it is capable of
inducing myogenesis in other cell types and may interact
with other stem cell lineages [10,11]. However, its role in
the morphologically normal colon is poorly studied as all
the studies have been carried out to look at its epigenetic
marking in colorectal adenomas & cancer. Ahuja et al.
[8] have shown significant hypermethylation of MYOD-1
in colon cancer tissue compared to adjacent normal mu-
cosa and this also increases with in age.
Unfortunately there is a paucity of robust studies look-
ing at the role of these genes in the colon and the state
of methylation in healthy individuals as this would help
appreciate the epigenetic changes with certain riskentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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to look at the gene specific methylation patterns of
MYOD-1 gene within the colon in normal individuals, in
an attempt to understand its relationship with known
risk factors of colon cancer including age, lifestyle and
anthropometric measures (waist to hip ratio (WHR)).Results
No outliers were identified for methylation of the pro-
moter regions MYOD-1. Frequency histograms for the
methylation data are shown in Figure 1. The observed
distribution observed for MYOD-1 was 60% of indivi-
duals with no detectable levels of methylation, 30% with
methylation levels of 10 – 25% and a small proportion
(< 5%) with higher levels of methylation; between 50 –
75%.Age and gene specific methylation pattern for MYOD −1
Logistic regression analysis demonstrated that methyla-
tion of MYOD-1 was highly significantly associated with
age (p< 0.001) with a greater proportion of individuals
over the age of 40 having detectable methylation. No as-
sociation with sex was noted after adjusting for age. As it
is well recognised that the incidence of colorectal can-
cers doubles after the age of 40, further analysis was per-
formed in these two groups– see Table 1. A three year
follow up of these patients revealed that none of these
patients developed colon cancer.Figure 1 (attached): Percentage of methylation of MYOD-1.Anthropometric measures and lifestyle factors and
methylation of MYOD −1
WHR but not BMI was significantly (p = 0.024) positively
associated with detectable MYOD-1 gene methylation
after adjusting for age. There were no associations be-
tween smoking habit, or alcohol consumption and de-
tectable MYOD-1 methylation.
Discussion
This study is the largest to date which has endeavoured
to characterise patterns of methylation of MYOD-1 gene
in individuals with normal colorectal mucosa. This gene
has been shown previously to demonstrate an increase in
methylation with age and in colorectal tumour tissue.
The majority of individuals in this study had either no or
low detectable methylation of MYOD-1 which implies
that in normal individuals this gene is not silenced
through hypermethylation and may have a distinct role
in disease whether it is age related, inflammatory or neo-
plastic. To date no studies have looked at the role of
MYOD-1 in colonic mucosa and whether it plays a role
as a tumour suppressor.
We have demonstrated that hypermethylation on
MYOD-1 was significantly higher in subjects aged over
40. For every decade increase in age of this study popula-
tion, there was a 10% increase in percentage detectable
methylation [12]. This is consistent with the study per-
formed by Ahuja et al. [8] and Hiranuma et al. [9] which
showed a significant age related methylation of MYOD-1
in normal colonic mucosa and neoplastic mucosa. Age
accounted for up to 11% and WHR 13% of the propor-
tion of variation in MYOD-1 methylation. WHR is an
important index of marker for colorectal cancers and
methylation of certain genes (HMLH1) have been
observed more frequently in those who are overweight
[13].
Colorectal cancers are amongst the few cancers sub-
jected to the intensive DNA methylation profiling, where
changes in methylation in tumour samples were classi-
fied as age related as well as the cancer specific [14].
This methylation profile of multiple genes including
MYOD-1 is called “CpG island methylation phenotype
(CIMP)”, and it is suggested that an unknown genetic
mechanism in colorectal cancer may contribute to the
clustering profile of the DNA methylation of the multiple
genes together [15]. One such study by Xiao-Li Xu [16]
that looked at the methylation profile of 31 genes
demonstrated that altered promoter CpG island methyla-
tion patterns of 17 genes (including MYOD-1) were
common with distinguished hallmarks specific to the
early phase of colon carcinogenesis. However there was
no significant correlation detected between the changes
in the methylation patterns with any given clinical-
pathological features apart from ageing. This adds
Table 1 Summary of percentage methylation for MYOD-1
and subgroup analysis of those under and over 40 years
of age
MYOD-1% (sd)
Male 8.60 (14)
Female 6.10 (9.1)
Total 7.31 (11)
Age Group
< 40 years 3.59 (11)
≥ 40 years 8.48 (11)
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strated that methylation of this gene increases with age
and is present in colorectal cancers.
Our study reinforces the significance of methylation of
certain genes that may lead to development of colorectal
cancer. The role of MYOD-1 gene in the colon is not
well understood. One study showed that it played a role
in the intestine smooth muscle development in ducks as
the gene was highly expressed in the small intestines
during the embryonic phase. Gene expression dropped
rapidly following embryogenesis but it is unclear if it
played an active role in adult development [17]. The sig-
nificance of promoter methylation of MYOD-1 as its
function in normal colonic mucosa remains unclear.
As this was primarily an observational study there
were a few limitations with it. We did not expect
MYOD-1 to be methylated in normal colonic tissue and
this was a novel finding. Further studies conducted to
examine the role of MYOD-1 methylation as a biomarker
should be case controlled against a colorectal cancer
population in order to draw sensitivities and predictive
values. Future studies should also compare MYOD-1
with MLH-1 methylation to see how this correlates to-
gether with increasing risk of colorectal cancer. Taken
together our findings lends support to the hypothesis
that promoter methylation of MYOD-1 may be an early
biomarker of CRC risk since we have shown positive as-
sociation with ageing and increasing WHR, both of
which are established risk factors for developing colon
cancer [18].Table 2 Summary of subject characteristics
Characteristics (n = 218)
Male 105
Female 113
Age <40 52
Age >40 166
Mean age (sd) 50 (13)
Mean BMI (sd) 28 (6)
Mean WHR 0.89 (0.09)
Smokers 51 (23%)Future studies should also include measurement of
mRNA levels of MYOD-1 gene in normal colonic mu-
cosa and specifically in colorectal cancers and correlation
in mutated crypts.Conclusion
We have for the first time demonstrated that promoter
methylation of MYOD-1 gene is a potential biomarker
for detecting risk of colorectal cancer and warrants fur-
ther research to establish its role into clinical practice.Methods
218 subjects (105 male, 113 female) were analysed as
part of the BORICC study. All patients had normal
endoscopic examinations – main symptom was overt
rectal bleeding. They did not have any significant past
medical history and their investigations were all normal.
Histological findings of colonic mucosal biopsies were
also reported as normal. The baseline characteristics of
these subjects are defined in Table 2. Gene specific DNA
methylation was quantified in DNA from colonic muco-
sal biopsies and was expressed as percentage methylation
of MYOD-1. Additional measurements made include
demographic details, smoking habit and anthropometric
measures.Assessment of DNA methylation
Tissue mucosal samples weighed 3–5 mg and DNA
was extracted as per the manufacturer’s protocol
(QIAGEN, QIAmpW DNA mini kit). Proteinase K was
added and samples were heated to 56oC overnight to
ensure complete tissue lysis. Additional RNAase treat-
ment was carried out to ensure RNA free DNA samples.
Only samples which had an A260/280 wavelength
(EppendorfW Biophotometer) ratio greater than 1.7 were
utilised.
DNA methylation at specific gene loci was quantified
by the COBRA technique (Combined Bisulphite Modi-
fied Restriction Enzyme Analysis) described by Xiong
et al. [19] in which DNA was treated with sodium bisul-
phite followed by PCR and restriction enzyme digestion.
The genomic region of interest was PCR amplified using
primer sets designed specifically to contain no CpG
dinucleotides. This step ensured that all templates were
amplified equally regardless of the methylation status of
the original genomic sequence. Following digestion with
restriction enzymes separation of the digestion products
using agarose gel electrophoresis, the DNA bands were
visualised using Sybr green staining and the bands repre-
senting methylated and unmethylated sequences quanti-
fied using UVI software (UVI Tech Ltd.). In this study,
the loci of interest were in the promoter regions of the
MYOD-1 gene.
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SPSS v15 was used for all data analysis. For the purpose
of statistical analysis, MYOD-1 methylation was cate-
gorised binomially i.e. those samples with no detectable
methylation (zero value) and those with detectable
methylation (given a value of 1). Binary logistic regres-
sion was employed to determine its relationship with de-
pendant variables (age, anthropometric measures etc.).
Statistical significance was defined as p ≤ 0.05.Statement of ethical approval
Northumberland Local Research Ethics Committee, UK.
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